Last updated on June 2019

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures


Brief description of study

Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.

Detailed Study Description

EP0077 is a 12 months, multicenter, noninterventional study (NIS) conducted at specialized sites in approximately 10 European countries. Patients will be treated according to usual medical diagnostic procedures and therapy; commercially available brivaracetam will be prescribed according to normal clinical practice and the current Summary of Product Characteristics (SmPC) in Europe for brivaracetam (BRV). The prescription of BRV is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures are applied to the patients.

The primary objective of this study is to determine BRV retention over a 12 month period as a measure of effectiveness in a real world setting. The secondary objective of this study is to assess seizure control with BRV treatment.

Clinical Study Identifier: NCT02687711

Find a site near you

Start Over

Ep0077 4504

Aarhus, Denmark
  Connect »

Ep0077 4501

Glostrup, Denmark
  Connect »

Ep0077 4506

Hillerod, Denmark
  Connect »

Ep0077 4503

Odense, Denmark
  Connect »

Ep0077 4906

Berlin, Germany
  Connect »

Ep0077 4914

Berlin, Germany
  Connect »

Ep0077 4909

Freiburg, Germany
  Connect »

Ep0077 4913

Hamburg, Germany
  Connect »

Ep0077 4912

Radeberg, Germany
  Connect »

Ep0077 4904

Ravensburg, Germany
  Connect »

Ep0077 3501

Dublin, Ireland
  Connect »

Ep0077 3101

Heeze, Netherlands
  Connect »

Ep0077 4414

Cardiff, United Kingdom
  Connect »

Ep0077 4404

Dundee, United Kingdom
  Connect »

Ep0077 4406

Dundee, United Kingdom
  Connect »

Ep0077 4413

Edinburgh, United Kingdom
  Connect »

Ep0077 4401

Glasgow, United Kingdom
  Connect »

Ep0077 4416

Inverness, United Kingdom
  Connect »

Ep0077 4417

Inverness, United Kingdom
  Connect »

Ep0077 4409

London, United Kingdom
  Connect »

Ep0077 4411

London, United Kingdom
  Connect »

Ep0077 4403

Salford, United Kingdom
  Connect »

Ep0077 4407

Sheffield, United Kingdom
  Connect »

Ep0077 4412

Stoke-on-Trent, United Kingdom
  Connect »

Ep0077 4402

Truro, United Kingdom
  Connect »

Ep0077 3606

Szeged, Hungary
  Connect »

Ep0077 3102

Maastricht, Netherlands
  Connect »

Ep0077 4408

Birmingham, United Kingdom
  Connect »

Ep0077 3605

Budapest, Hungary
  Connect »

Ep0077 4701

Fredrikstad, Norway
  Connect »

Ep0077 3407

Barakaldo, Spain
  Connect »

Ep0077 3505

Dublin, Ireland
  Connect »

Ep0077 4905

Tübingen, Germany
  Connect »

Ep0077 3608

Kecskemét, Hungary
  Connect »

Ep0077 3607

Mosdós, Hungary
  Connect »

Ep0077 3602

Nyíregyháza, Hungary
  Connect »

Ep0077 3402

A Coruña, Spain
  Connect »

Ep0077 3412

Córdoba, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.